Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Unknown 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 15Thoracic 3Breast 2Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 30Small Cell Lung Carcinoma 13Recurrence 3Melanoma 3Lung Neoplasms 3Advanced Lung Cancer 3NSCLC 2Lymphoma 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Treatment-naive Advanced Non-small Cell Lung Cancer 1Thoracic Neoplasms 1Stage IB-IIIB NSCLC 1Small Cell Lung Cancer Limited Stage 1Sarcoma 1SCLC, Extensive Stage 1Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) 1Ovarian Neoplasms 1Non-small Lung Cancer 1Non Squamous Non Small Cell Lung Cancer 1Non Small Cell Lung Cancer Recurrent 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mesothelioma, Malignant 1Lung Diseases 1Local Advanced Non-small Cell Lung Cancer 1Liver Neoplasms 1Kidney Neoplasms 1

Interventions

pembrolizumab 92Nivolumab 57Cyclophosphamide 22Ipilimumab 17atezolizumab 15Magnetic Resonance Spectroscopy 14Specimen Handling 13Radiosurgery 13Paclitaxel 13Interleukin-2 12Docetaxel 12fludarabine 11Carboplatin 11Pemetrexed 10spartalizumab 9Biopsy 9durvalumab 8Cisplatin 8Radiotherapy 7Immune Checkpoint Inhibitors 7Blood Specimen Collection 7cemiplimab 6avelumab 6aldesleukin 6Taxes 6Gemcitabine 6Drug Therapy 6Bevacizumab 6trametinib 5tislelizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Melanoma × toripalimab × Thoracic × Clear all
NCT05955105 2024-05-21

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Innolake Biopharm

Phase 1/2 Recruiting
200 enrolled
BreastDermatologicGynecologicHead & NeckSarcomaThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04137900 2024-02-05

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

TopAlliance Biosciences

Phase 1 Unknown
499 enrolled
DermatologicLymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Neoplasm Metastasis

NCT05798533 2023-07-10

Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)

BGI, China

Phase 1 Unknown
6 enrolled
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡